## **CLINICAL TRIAL**

NCT03364153

**Retinal RED** 





## Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Rare Eye Disease concerned by the trial: Status of the trial: Active, not recruiting

Stargardt Disease 1 Orphan drug recognition: Yes

Inclusion criteria: <u>click here to see detailed criteria</u>

Exclusion criteria: <u>click here to see detailed criteria</u>

Inclusion

opening date: 10/01/2018



Inclusion closing

date (previsional): 30/09/2020

Children

Adults



## Within ERN-EYE members



## Locations of the trial:

CHNO des XV XX - Centre Hospitalier National d'Ophtalmologie

Paris, France

**Moorfields Eye Hospital** 

London, United Kingdom, EC1V 2PD

Universitätsklinikum Tübingen

Tübingen, Germany

Azienda Ospedaliero Universitaria Careggi

Florence, Italy

Azienda Ospedaliera Universitaria, Universita degli studi della Campania Luigi Vanvitelli

Naples, Italy



Funder type: Industry